FDA’s ongoing efforts to promote broad and inclusive eligibility criteria in clinical trials – Friends of Cancer Research
American Society of Clinical Oncology (ASCO) shared a post by Friends of Cancer Research on LinkedIn, adding:
“Thank you, Friends of Cancer Research, for collaborating to broaden eligibility for cancer clinical trials.
This effort is crucial for patients with cancer, and we urge the FDA to prompt sponsors to modify their trial design to make trials more inclusive and representative of the broader patient population.
Read more here.”
Quoting Friends of Cancer Research’s post:
“We are grateful for FDA’s ongoing efforts to promote broad and inclusive eligibility criteria in clinical trials, enhancing the generalizability of results while safeguarding participant safety.
American Society of Clinical Oncology (ASCO) and Friends of Cancer Research recently submitted our public comments in response to FDA’s latest draft guidance documents that focus on performance status, laboratory values and criteria on washout periods and concomitant medications.
We look forward to continuing to collaborate with FDA and other stakeholders to advance more patient-centered clinical trials, ensuring that research benefits everyone.”
Additional information.
Source: ASCO/LinkedIn and Friends of Cancer Research/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023